european association for the study of the liver

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

680 documents for european association for the study of the liver

- Salix Reviews the International Liver Congress 2011 Of the European Association for the Study of the Liver.
Open-Label Maintenance Trial Data Demonstrated Long-Term Efficacy and Survival in Patients Treated with Rifaximin for the Maintenance of Remission Fro...
- Business Wire
- April 04, 2011
- Idera Pharmaceuticals Announces IMO-2125 Data Presentation at the 46th Annual Meeting of the European Association for the Study of the Liver.
CAMBRIDGE, Mass. -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that data from its Phase 1 clinical trial of IMO-2125, its novel immune...
- Business Wire
- March 08, 2011
- Clinical implications of resistance patterns against HBV-polymerase inhibitors for the treatment of chronic hepatitis B.
... treatment options and lead to progressive liver disease in patients running out of effective treat... alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon alfa-2a, lamivudine, and the ...42nd Annual Meeting of the European Association for the Study of the Liver 2007, Barce...
- Journal of HIV Therapy
- Vol. 12 Nbr. 4, December 2007

- Inhibitex Announces Data Presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL).
ATLANTA -- Inhibitex, Inc. (NASDAQ: INHX) announced today the presentation of data from its single ascending dose Phase 1a study of INX-189 in healthy...
- Business Wire
- March 31, 2011
- Flamel Technologies Presents Results of a Clinical Trial of its Medusa(R) formulation of Interferon Alpha XL at the European Association for the Study of the Liver.
MILAN, Italy -- Flamel Technologies (NASDAQ:FLML) announced that Professor Christian Trepo presented the results of its clinical trial of Flamel's Med...
- Business Wire
- April 25, 2008
- Presidio Pharmaceuticals, Inc. to Present Posters at the 46th European Association for the Study of the Liver (EASL) Meeting.
SAN FRANCISCO -- Presidio Pharmaceuticals, Inc. announced today that Richard J. Colonno, Ph.D., Chief Scientific Officer, will present two posters at ...
- Business Wire
- March 24, 2011
- Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease Inhibitor Telaprevir to be Presented at 42nd Annual Meeting of the European Association for the Study of the Liver (EASL).
In vitro results support expansion of telaprevir clinical development into genotype 2, 3 and 4 HCV patients BARCELONA, Spain -- New data supporting ...
- Business Wire
- April 11, 2007
- Presidio Pharmaceuticals, Inc. to Present at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL).
SAN FRANCISCO -- Presidio Pharmaceuticals, Inc. announced today that Richard Colonno, PhD, Chief Scientific Officer, will present a summary of the pro...
- Business Wire
- April 08, 2010
- Galectin Therapeutics Provides Corporate Update.
...Liver Fibrosis: Bold New Strategy in an Unmet Medical Ne... compelling preclinical data at the European Association for the Study of the Liver in Lisbon, ...
- Business Wire
- December 19, 2011
- SCYNEXIS Announces Acceptance of Abstracts Related to its Hepatitis C Clinical Candidate, SCY-635, for Presentation at 45th Annual Meeting of the European Association for the Study of the Liver.
RESEARCH TRIANGLE PARK, N.C. -- Drug discovery company, SCYNEXIS, Inc. today announced that multiple abstracts related to the Company's cyclophilin in...
- Business Wire
- April 05, 2010